Sponsor hub
Biogen clinical trial failures
Review 80 stopped clinical trials from Biogen, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 23 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 38
- OTHER/UNKNOWN
- 19
- EFFICACY/FUTILITY
- 14
- SAFETY
- 9
Notable sponsors
- Biogen
- 80
Related phases
- Phase II
- 29
- Phase III
- 26
- Phase I
- 16
- Phase IV
- 9
Crawlable stopped-trial records
Open ExploreShowing up to 80 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase III Multiple Sclerosis, Relapsing-Remitting trial by Biogen. Stop reason: OPERATIONAL.
Due to sponsor decision, not for efficacy or safety reasons.
Phase I Amyotrophic Lateral Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's decision
Phase III Pulmonary Hypertension trial by Biogen. Stop reason: OPERATIONAL.
The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Phase III Connective Tissue Disease-Associated Pulmonary Arterial Hypertension trial by Biogen. Stop reason: OPERATIONAL.
Exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health
Phase III Chronic Kidney Diseases trial by Biogen. Stop reason: OTHER/UNKNOWN.
Discontinuation of all bardoxolone chronic kidney disease programs
Phase III Autosomal Dominant Polycystic Kidney trial by Biogen. Stop reason: OTHER/UNKNOWN.
Discontinuation of all bardoxolone chronic kidney disease programs
Phase II Malignant Melanoma trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Liver Disease trial by Biogen. Stop reason: OPERATIONAL.
Enrollment discontinued after second cohort completed.
Phase I Leptomeningeal Carcinomatosis trial by Biogen. Stop reason: OPERATIONAL.
Business Decision
Phase II Brain Metastases trial by Biogen. Stop reason: OPERATIONAL.
Business Decision
Phase II Renal Insufficiency, Chronic trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase III Renal Insufficiency, Chronic trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase I Renal Insufficiency, Chronic trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase II End-Stage Renal Disease trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase I Renal Insufficiency, Chronic trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase I Pancreatic Neoplasms trial by Biogen. Stop reason: OTHER/UNKNOWN.
To pursue other indications
Phase III Alzheimer's Disease trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's Decision
Phase III Alzheimer's Disease trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's Decision
Phase III Parkinson Disease trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase IV Multiple Sclerosis, Relapsing-Remitting trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's decision
Phase II Relapsing Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's decision.
Phase IV Relapsing-remitting Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor decision to withdraw study at this time.
Phase II Ischemic Stroke trial by Biogen. Stop reason: OPERATIONAL.
Sponsor decision
Phase III Major Depressive Disorder trial by Biogen. Stop reason: OPERATIONAL.
Internal company decision
Phase III Major Depressive Disorder trial by Biogen. Stop reason: OPERATIONAL.
internal company decision
Phase I Chronic Kidney Disease trial by Biogen. Stop reason: SAFETY.
IDMC recommendation for safety concerns
Phase II Renal Insufficiency trial by Biogen. Stop reason: OPERATIONAL.
Company Decision
Phase II Parkinson's Disease trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Spinocerebellar Ataxia Type 3 trial by Biogen. Stop reason: OPERATIONAL.
Sponsor's Decision
Phase III Multiple Sclerosis, Relapsing-Remitting trial by Biogen. Stop reason: OPERATIONAL.
Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.
Phase II Relapsing Multiple Sclerosis trial by Biogen. Stop reason: OTHER/UNKNOWN.
Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns.
Phase III Trigeminal Neuralgia trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Trigeminal Neuralgia trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Amyotrophic Lateral Sclerosis trial by Biogen. Stop reason: OTHER/UNKNOWN.
There was no evidence of benefit across efficacy endpoints in the randomized trial, 245AS101. Accordingly, Biogen has made the difficult decision to discontinue the BIIB078 program including this open label extension trial, 245AS102.
Phase II Alzheimer's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.
Phase II Multiple Sclerosis trial by Biogen. Stop reason: EFFICACY/FUTILITY.
The top-line results from the Part 1 did not meet the pre-specified primary endpoint nor the key secondary endpoints. The decision to discontinue study 215MS202 Part 2 was not based on safety concerns.
Phase II Parkinson's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.
Phase II Cognitive Dysfunction trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
Phase III Alzheimer's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
Phase III Alzheimer's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
Phase I Parkinson's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Affiliated study NCT03318523 did not meet its primary outcome measure of change from baseline measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and did not demonstrate efficacy on secondary outcome measures
Phase II Small Fiber Neuropathy trial by Biogen. Stop reason: OPERATIONAL.
Sponsor decision to close study early; not due to safety concerns
Phase I Healthy Volunteers trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Spinal Muscular Atrophy trial by Biogen. Stop reason: EFFICACY/FUTILITY.
After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study
Phase II Spinal Muscular Atrophy trial by Biogen. Stop reason: OTHER/UNKNOWN.
The study was terminated early to roll over participants to open label extension study NCT02594124.
Phase II Supranuclear Palsy, Progressive trial by Biogen. Stop reason: EFFICACY/FUTILITY.
251PP301(PASSPORT) primary endpoint was not met;Biogen decision to close the study early. There were no safety concerns with the PASSPORT study.
Phase II Idiopathic Pulmonary Fibrosis trial by Biogen. Stop reason: SAFETY.
Study was stopped because of safety concerns.
Phase I Alzheimer's Disease trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
Phase I Supranuclear Palsy, Progressive trial by Biogen. Stop reason: EFFICACY/FUTILITY.
251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.
Phase II Cognitive Impairment Associated With Schizophrenia (CIAS) trial by Biogen. Stop reason: OPERATIONAL.
Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not due to any safety concern or change in benefit:risk assessment.
Phase I Healthy Volunteers trial by Biogen. Stop reason: OTHER/UNKNOWN.
See termination reason in detailed description.
Phase III Relapsing-Remitting Multiple Sclerosis trial by Biogen. Stop reason: OTHER/UNKNOWN.
Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.
Phase III Relapsing-Remitting Multiple Sclerosis (RRMS) trial by Biogen. Stop reason: OPERATIONAL.
Study terminated in line with Biogen decision to withdraw Zinbryta from the market and not to pursue further studies of daclizumab in MS.
Phase II Neuropathic Pain From Lumbosacral Radiculopathy trial by Biogen. Stop reason: OPERATIONAL.
The parent study did not meet its primary or secondary efficacy endpoints and therefore Sponsor decision to discontinue development in this indication.
Phase I Pain, Neuropathic trial by Biogen. Stop reason: SAFETY.
During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion
Phase III Secondary Progressive Multiple Sclerosis trial by Biogen. Stop reason: OTHER/UNKNOWN.
The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
Phase IV Relapsing-Remitting Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Business Decision
Phase IV Relapsing Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Business Decision
Phase IV Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor decision
Phase III Multiple Sclerosis, Secondary Progressive trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Healthy trial by Biogen. Stop reason: SAFETY.
Clinical study terminated due to preclinical safety findings in non-human primates.
Phase II Lupus Nephritis trial by Biogen. Stop reason: OTHER/UNKNOWN.
Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate sufficient efficacy to warrant continuation of the study
Phase II Lupus Nephritis trial by Biogen. Stop reason: OTHER/UNKNOWN.
Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: OTHER/UNKNOWN.
The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
Phase III Relapsing-Remitting Multiple Sclerosis trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Crohn's Disease trial by Biogen. Stop reason: OPERATIONAL.
Study sponsor decided to withdraw the current study prior to enrollment of first participant.
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: OTHER/UNKNOWN.
The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
Phase IV Relapsing-Remitting Multiple Sclerosis (RRMS) trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Relapsing-Remitting Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Feasibility
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Analysis of data from 104RA202 failed to meet primary endpoint
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Analysis of data from 104RA203 failed to meet primary endpoint.
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: EFFICACY/FUTILITY.
Interim analysis of data failed to meet primary endpoint.
Phase IV Relapsing Remitting Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Lymphoma, Non-Hodgkin's trial by Biogen. Stop reason: OPERATIONAL.
Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
Phase II Chronic Lymphocytic Leukemia trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Lymphocytic Leukemia trial by Biogen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Lymphoma, Non-Hodgkin's trial by Biogen. Stop reason: OPERATIONAL.
Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
Phase II Rheumatoid Arthritis trial by Biogen. Stop reason: OPERATIONAL.
Sponsor decided to end long term extension phase for business reasons unrelated to safety.
Phase IV Relapsing-Remitting Multiple Sclerosis trial by Biogen. Stop reason: OPERATIONAL.
The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not a result of any safety or efficacy concerns.